Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Mediterranean diet and antihypertensive drug use: a randomized controlled trial

  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Babio, Nancy
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Díez Espino, Javier
  • González, José I.
  • Becerra-Tomás, Nerea
  • Cofán Pujol, Montserrat
  • Díaz López, Andrés
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Objective: To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk. Methods: In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of: initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events. Results: Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates: 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74--0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates: 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60--0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003). Conclusion: In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals: A cohort study

  • Ribó-Coll, Margarita
  • Castro-Barquero, Sara
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Díaz López, Andrés
  • Lapetra, José
  • Muñoz-Bravo, Carlos
  • Arós, Fernando
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Fernandez-Lazaro, Cesar I.
  • Portolés, Olga
  • Babio, Nancy
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular-related medications., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Modification of high-density lipoprotein functions by diet and other lifestyle changes: A systematic review of randomized controlled trials

  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Soria Florido, María Trinidad
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
High-density lipoprotein (HDL) functional traits have emerged as relevant elements that may explain HDL antiatherogenic capacity better than HDL cholesterol levels. These properties have been improved in several lifestyle intervention trials. The aim of this systematic review is to summarize the results of such trials of the most commonly used dietary modifications (fatty acids, cholesterol, antioxidants, alcohol, and calorie restriction) and physical activity. Articles were screened from the Medline database until March 2021, and 118 randomized controlled trials were selected. Results from HDL functions and associated functional components were extracted, including cholesterol efflux capacity, cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, HDL antioxidant capacity, HDL oxidation status, paraoxonase-1 activity, HDL anti-inflammatory and endothelial protection capacity, HDL-associated phospholipase A2, HDL-associated serum amyloid A, and HDL-alpha-1-antitrypsin. In mainly short-term clinical trials, the consumption of monounsaturated and polyunsaturated fatty acids (particularly omega-3 in fish), and dietary antioxidants showed benefits to HDL functionality, especially in subjects with cardiovascular risk factors. In this regard, antioxidant-rich dietary patterns were able to improve HDL function in both healthy individuals and subjects at high cardiovascular risk. In addition, in randomized trial assays performed mainly in healthy individuals, reverse cholesterol transport with ethanol in moderate quantities enhanced HDL function. Nevertheless, the evidence summarized was of unclear quality and short-term nature and presented heterogeneity in lifestyle modifications, trial designs, and biochemical techniques for the assessment of HDL functions. Such findings should therefore be interpreted with caution. Large-scale, long-term, randomized, controlled trials in different populations and individuals with diverse pathologies are warranted., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Energy balance and risk of mortality in Spanish older adults

  • Lassale, Camille
  • Hernáez, Álvaro
  • Toledo, Estefanía
  • Castañer, Olga
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Estruch Riba, Ramon
  • Ros Rahola, Emilio
  • Alonso Gómez, Ángel M.
  • Lapetra, José
  • Cueto, Raquel
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gea, Alfredo
  • Corella Piquer, Dolores
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Schröder, Helmut
Clinical data on the direct health effects of energy deficit or surplus beyond its impact on body weight are scarce. We aimed to assess the association with all-cause, cardiovascular and cancer mortality of (1) sustained energy deficit or surplus, calculated according to each individual’s en-ergy intake (EI) and theoretical energy expenditure (TEE), and (2) mid-term change in total EI in a prospective study. In 7119 participants in the PREDIMED Study (PREvención con DIeta MEDi-terránea) with a mean age of 67 years, energy intake was derived from a 137-item food frequency questionnaire. TEE was calculated as a function of age, sex, height, body weight and physical ac-tivity. The main exposure was the proportion of energy requirement covered by energy intake, cumulative throughout the follow-up. The secondary exposure was the change in energy intake from baseline. Cox proportional hazard models were used to estimate hazard ratios and 95% con-fidence intervals for all-cause, cardiovascular and cancer mortality. Over a median follow-up of 4.8 years, there were 239 deaths (excluding the first 2 years). An energy intake exceeding energy needs was associated with an increase in mortality risk (continuous HR10% over energy needs = 1.10; 95% CI 1.02, 1.18), driven by cardiovascular death (HR = 1.26; 95% CI 1.11, 1.43). However, consum-ing energy below estimated needs was not associated with a lower risk. Increments over time in energy intake were associated with greater all-cause mortality (HR10% increase = 1.09; 95% CI 1.02, 1.17). However, there was no evidence that a substantial negative change in energy intake would reduce mortality risk. To conclude, in an older Mediterranean cohort, energy surplus or increase over a 5-year period was associated with greater risk of mortality, particularly cardiovascular mortality. Energy deficit, or reduction in energy intake over time were not associated with mortal-ity risk., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Mediterranean diet decreases the initiation of use of vitamin K epoxide reductase inhibitors and their associated cardiovascular risk: a randomized controlled trial

  • Castro-Barquero, Sara
  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Martínez-González, Miguel Ángel, 1957-
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol Sala, Miguel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Basterra-Gortari, Francisco Javier
  • Portolés, Olga
  • Babio, Nancy
  • Cofán Pujol, Montserrat
  • Ros Rahola, Emilio
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvención con DIeta MEDiterránea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). We also assess whether MedDiet modifies the association between the antithrombotic drug baseline use and incident cardiovascular events. The MedDiet intervention enriched with extra-virgin olive oil decreased the risk of initiating the use of vitamin K epoxide reductase inhibitors relative to control diet (HR: 0.68 [0.46–0.998]). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HRcontrol diet: 4.22 [1.92–9.30], HRMedDiets: 1.71 [0.83–3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Mediterranean diet maintained platelet count within a healthy range and decreased thrombocytopenia-related mortality risk: a randomized controlled trial

  • Hernáez, Álvaro
  • Lassale, Camille
  • Castro-Barquero, Sara
  • Ros Rahola, Emilio
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Vázquez Ruiz, Zenaida
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Razquin, Cristina
  • Corella Piquer, Dolores
  • Guasch-Ferré, Marta
  • Cofán Pujol, Montserrat
  • Estruch Riba, Ramon
There is little information on the dietary modulation of thrombosis-related risk factors such as platelet count. We aimed to assess the effects of Mediterranean diet (MedDiet) on platelet count and related outcomes in an older population at high cardiovascular risk. In participants of the PREDIMED (PREvención con DIeta MEDiterránea) study, we assessed whether an intervention with a MedDiet enriched with extra-virgin olive oil or nuts, relative to a low-fat control diet, modulated platelet count (n = 4189), the risk of developing thrombocytosis and thrombocytopenia (n = 3086), and the association between these alterations and all-cause mortality (median follow-up time: 3.0 years). Although platelet count increased over time (+0.98·109 units/L·year [95% confidence interval: 0.12; 1.84]), MedDiet interventions moderated this increase, particularly in individuals with near-high baseline count (both MedDiets combined: −3.20·109 units/L·year [−5.81; −0.59]). Thrombocytopenia incidence was lower in the MedDiet interventions (incidence rates: 2.23% in control diet, 0.91% in MedDiets combined; hazard ratio: 0.44 [0.23; 0.83]). Finally, thrombocytopenia was associated with a higher risk of all-cause mortality (hazard ratio: 4.71 [2.69; 8.24]), but this relationship was attenuated in those allocated to MedDiet (p-interaction = 0.018). In brief, MedDiet maintained platelet counts within a healthy range and attenuated platelet-related mortality in older adults at high cardiovascular risk.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Modification of high-density lipoprotein functions by diet and other lifestyle changes: A systematic review of randomized controlled trials

  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Soria Florido, María Trinidad
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
High-density lipoprotein (HDL) functional traits have emerged as relevant elements that may explain HDL antiatherogenic capacity better than HDL cholesterol levels. These properties have been improved in several lifestyle intervention trials. The aim of this systematic review is to summarize the results of such trials of the most commonly used dietary modifications (fatty acids, cholesterol, antioxidants, alcohol, and calorie restriction) and physical activity. Articles were screened from the Medline database until March 2021, and 118 randomized controlled trials were selected. Results from HDL functions and associated functional components were extracted, including cholesterol efflux capacity, cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, HDL antioxidant capacity, HDL oxidation status, paraoxonase-1 activity, HDL anti-inflammatory and endothelial protection capacity, HDL-associated phospholipase A2, HDL-associated serum amyloid A, and HDL-alpha-1-antitrypsin. In mainly short-term clinical trials, the consumption of monounsaturated and polyunsaturated fatty acids (particularly omega-3 in fish), and dietary antioxidants showed benefits to HDL functionality, especially in subjects with cardiovascular risk factors. In this regard, antioxidant-rich dietary patterns were able to improve HDL function in both healthy individuals and subjects at high cardiovascular risk. In addition, in randomized trial assays performed mainly in healthy individuals, reverse cholesterol transport with ethanol in moderate quantities enhanced HDL function. Nevertheless, the evidence summarized was of unclear quality and short-term nature and presented heterogeneity in lifestyle modifications, trial designs, and biochemical techniques for the assessment of HDL functions. Such findings should therefore be interpreted with caution. Large-scale, long-term, randomized, controlled trials in different populations and individuals with diverse pathologies are warranted., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals: A cohort study

  • Ribó-Coll, Margarita
  • Castro-Barquero, Sara
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Díaz López, Andrés
  • Lapetra, José
  • Muñoz-Bravo, Carlos
  • Arós, Fernando
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Fernandez-Lazaro, Cesar I.
  • Portolés, Olga
  • Babio, Nancy
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular-related medications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Energy balance and risk of mortality in Spanish older adults

  • Lassale, Camille
  • Hernáez, Álvaro
  • Toledo, Estefanía
  • Castañer, Olga
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Estruch Riba, Ramon
  • Ros Rahola, Emilio
  • Alonso Gómez, Ángel M.
  • Lapetra, José
  • Cueto, Raquel
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gea, Alfredo
  • Corella Piquer, Dolores
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Schröder, Helmut
Clinical data on the direct health effects of energy deficit or surplus beyond its impact on body weight are scarce. We aimed to assess the association with all-cause, cardiovascular and cancer mortality of (1) sustained energy deficit or surplus, calculated according to each individual’s en-ergy intake (EI) and theoretical energy expenditure (TEE), and (2) mid-term change in total EI in a prospective study. In 7119 participants in the PREDIMED Study (PREvención con DIeta MEDi-terránea) with a mean age of 67 years, energy intake was derived from a 137-item food frequency questionnaire. TEE was calculated as a function of age, sex, height, body weight and physical ac-tivity. The main exposure was the proportion of energy requirement covered by energy intake, cumulative throughout the follow-up. The secondary exposure was the change in energy intake from baseline. Cox proportional hazard models were used to estimate hazard ratios and 95% con-fidence intervals for all-cause, cardiovascular and cancer mortality. Over a median follow-up of 4.8 years, there were 239 deaths (excluding the first 2 years). An energy intake exceeding energy needs was associated with an increase in mortality risk (continuous HR10% over energy needs = 1.10; 95% CI 1.02, 1.18), driven by cardiovascular death (HR = 1.26; 95% CI 1.11, 1.43). However, consum-ing energy below estimated needs was not associated with a lower risk. Increments over time in energy intake were associated with greater all-cause mortality (HR10% increase = 1.09; 95% CI 1.02, 1.17). However, there was no evidence that a substantial negative change in energy intake would reduce mortality risk. To conclude, in an older Mediterranean cohort, energy surplus or increase over a 5-year period was associated with greater risk of mortality, particularly cardiovascular mortality. Energy deficit, or reduction in energy intake over time were not associated with mortal-ity risk., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mediterranean diet maintained platelet count within a healthy range and decreased thrombocytopenia-related mortality risk: a randomized controlled trial

  • Hernáez, Álvaro
  • Lassale, Camille
  • Castro-Barquero, Sara
  • Ros Rahola, Emilio
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Vázquez Ruiz, Zenaida
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Razquin, Cristina
  • Corella Piquer, Dolores
  • Guasch-Ferré, Marta
  • Cofán Pujol, Montserrat
  • Estruch Riba, Ramon
There is little information on the dietary modulation of thrombosis-related risk factors such as platelet count. We aimed to assess the effects of Mediterranean diet (MedDiet) on platelet count and related outcomes in an older population at high cardiovascular risk. In participants of the PREDIMED (PREvención con DIeta MEDiterránea) study, we assessed whether an intervention with a MedDiet enriched with extra-virgin olive oil or nuts, relative to a low-fat control diet, modulated platelet count (n = 4189), the risk of developing thrombocytosis and thrombocytopenia (n = 3086), and the association between these alterations and all-cause mortality (median follow-up time: 3.0 years). Although platelet count increased over time (+0.98·109 units/L·year [95% confidence interval: 0.12; 1.84]), MedDiet interventions moderated this increase, particularly in individuals with near-high baseline count (both MedDiets combined: −3.20·109 units/L·year [−5.81; −0.59]). Thrombocytopenia incidence was lower in the MedDiet interventions (incidence rates: 2.23% in control diet, 0.91% in MedDiets combined; hazard ratio: 0.44 [0.23; 0.83]). Finally, thrombocytopenia was associated with a higher risk of all-cause mortality (hazard ratio: 4.71 [2.69; 8.24]), but this relationship was attenuated in those allocated to MedDiet (p-interaction = 0.018). In brief, MedDiet maintained platelet counts within a healthy range and attenuated platelet-related mortality in older adults at high cardiovascular risk.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mediterranean diet decreases the initiation of use of vitamin K epoxide reductase inhibitors and their associated cardiovascular risk: a randomized controlled trial

  • Castro-Barquero, Sara
  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Martínez-González, Miguel Ángel, 1957-
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol Sala, Miguel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Basterra-Gortari, Francisco Javier
  • Portolés, Olga
  • Babio, Nancy
  • Cofán Pujol, Montserrat
  • Ros Rahola, Emilio
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvención con DIeta MEDiterránea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). We also assess whether MedDiet modifies the association between the antithrombotic drug baseline use and incident cardiovascular events. The MedDiet intervention enriched with extra-virgin olive oil decreased the risk of initiating the use of vitamin K epoxide reductase inhibitors relative to control diet (HR: 0.68 [0.46–0.998]). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HRcontrol diet: 4.22 [1.92–9.30], HRMedDiets: 1.71 [0.83–3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mediterranean diet and antihypertensive drug use: a randomized controlled trial

  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Babio, Nancy
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Díez Espino, Javier
  • González, José I.
  • Becerra-Tomás, Nerea
  • Cofán Pujol, Montserrat
  • Díaz López, Andrés
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Objective: To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk. Methods: In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of: initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events. Results: Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates: 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74--0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates: 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60--0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003). Conclusion: In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phenol-Enriched Virgin Olive Oil Promotes Macrophage-Specific Reverse Cholesterol Transport In Vivo

  • Cedó, Lídia|||0000-0003-4354-3411
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Rubió, Laura
  • Metso, Jari
  • Santos, David|||0000-0003-1157-4969
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Motilva, Maria-José|||0000-0001-8985-7737
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Solà, Rosa|||0000-0002-8359-235X
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
The intake of olive oil (OO) enriched with phenolic compounds (PCs) promotes ex vivo HDL-mediated macrophage cholesterol efflux in humans. We aimed to determine the effects of PC-enriched virgin OO on reverse cholesterol transport (RevCT) from macrophages to feces in vivo. Female C57BL/6 mice were given intragastric doses of refined OO (ROO) and a functional unrefined virgin OO enriched with its own PC (FVOO) for 14 days. Our experiments included two independent groups of mice that received intragastric doses of the phenolic extract (PE) used to prepare the FVOO and the vehicle solution (saline), as control, for 14 days. FVOO intake led to a significant increase in serum HDL cholesterol and its ability to induce macrophage cholesterol efflux in vitro when compared with ROO group. This was concomitant with the enhanced macrophage-derived [ 3 H]cholesterol transport to feces in vivo. PE intake per se also increased HDL cholesterol levels and significantly promoted in vivo macrophage-to-feces RevCT rate when compared with saline group. PE upregulated the expression of the main macrophage transporter involved in macrophage cholesterol efflux, the ATP binding cassette a1. Our data provide direct evidence of the crucial role of OO PCs in the induction of macrophage-specific RevCT in vivo.